Clinical trial
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer…
NCT00078585 · Bavarian Nordic, Industry · Completed
Key facts
| NCT number | NCT00078585 |
|---|---|
| Title | PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy |
| Official title | A Phase II Randomized, Double Blind, Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC®-VF/TRICOM™ in Combination With GM-CSF in Patients With Androgen-Independent Adenocarcinoma of the Prostate |
| Lead sponsor | Bavarian Nordic, Industry |
| Collaborators | Therion Biologics Corporation Industry National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | PROSTVAC®-VF/TRICOM™ |
| Enrollment | 120 |
| Start date | Nov 1, 2003 |
| Primary completion | Jan 4, 2006 |
| Completion | Jan 1, 2009 |
| First posted | Mar 3, 2004 |
| Last update posted | Sep 11, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: